Delivery of Oligonucleotide Therapeutics
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: 10 June 2024 | Viewed by 154
Special Issue Editors
Interests: oligonucleotide aptamers; oligonucleotide analogs; nucleopeptides; metal-based drugs; DNA-small molecule interaction; DNA-protein interaction
Special Issues, Collections and Topics in MDPI journals
Interests: noncanonical nucleic acids; nucleic acid theranostics; small molecule–DNA interactions
Interests: noncanonical nucleic acids; cellular and molecular biology; medicinal chemistry
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Oligonucleotide therapeutics (OTs) are synthetic DNA or RNA strands with the potential to treat a wide range of diseases. OTs include several molecular entities, such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), anti‐microRNAs (antagomirs), microRNA mimics (agomirs), aptamers and unmethylated CpG‐containing oligonucleotides.
Until now, fifteen FDA-approved oligonucleotide drugs have been released on the market, with many other OTs being investigated.
OTs are promising candidates in the pharmaceutical context. Nevertheless, one of the greatest challenges in oligonucleotide therapy is the delivery of the active substances to the site of action, mainly due to their unfavorable pharmacokinetic profile and nuclease degradation.
To overcome these issues, many strategies have been reported in the literature, ranging from chemical modifications of the DNA/RNA backbone to bioconjugation or encapsulation in nanocarriers.
The continuous progress in this field is gradually unlocking the true potential of oligonucleotide-based therapeutics, opening new perspectives and expanding the range of possible applications.
Authors are invited to submit original papers, communications and reviews regarding the delivery of oligonucleotide therapeutics, to be published in this Special Issue of Pharmaceutics.
Dr. Domenica Musumeci
Dr. Ettore Napolitano
Dr. Anna Di Porzio
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- DNA
- RNA
- oligonucleotides
- nucleic acid-based therapeutics
- drug delivery
- biodistribution
- pharmacokinetic
